We performed a post hoc analysis of a single-center phase II trial (ClinicalTrials.gov identifier: NCT03503643) in which patients with unilateral grade group (GG) 2-4 PCa (n = 108) underwent hemigland ...
For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before the cancer comes back. Researchers at UCLA have found that a blend of a ...
Find out how ADT + ARPI outperforms ADT alone in mHSPC, boosting survival and treatment persistence. Read more on real-world ...
Fig 1. Summary of key guideline recommendations. ADT, androgen deprivation therapy; ARPI, androgen receptor pathway inhibitor; C, conditional; CRPC, castration ...
A small, early clinical trial led by the Icahn School of Medicine at Mount Sinai and collaborators has shown that directly ...
The Chosun Ilbo on MSN
Radioactive 'Missile' Therapy Targets Prostate Cancer
A 75-year-old man, Mr. A, had prostate cancer that had metastasized to his pelvis and spine. Multiple anticancer drugs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback